Bank of America just raised its EUR/USD forecast
BELLEVUE, Wash. - OSR Holdings, Inc. (NASDAQ:OSRH), a micro-cap healthcare company currently valued at $16.7 million, has issued 2,308,382 total shares to date under its structured financing arrangements, including 767,500 shares under its Equity Line of Credit (ELOC) agreement with White Lion GBM Innovation Fund, the company announced Thursday. According to InvestingPro data, the stock has declined over 92% year-to-date, though analysis suggests the shares may be undervalued at current levels.
The healthcare firm reported that the ELOC-related issuance represents less than 10% of the 9,500,000 registered share capacity since the agreement’s effective date of June 17.
The company’s structured financing includes 519,481 commitment shares, 745,193 shares from convertible notes, and 276,208 shares from warrant exercises.
"While structured financing mechanisms like ELOCs, warrants, and convertible notes inherently carry dilution risk, it’s important to emphasize that any future issuance under our ELOC is not purely dilutive," said Peter Hwang, CEO of OSRH, in the press release.
The company stated that proceeds from these financings are being invested into its business operations, including drug research and development, medical device initiatives, and digital asset ecosystems.
OSRH also provided an update on its pending transaction with Woori IO, noting that Woori IO’s clinical trial in Korea involves a partnership with a major technology company in the mobile and wearable devices sector. The company expects to complete the Stock Purchase Agreement by the end of October.
OSR Holdings describes itself as a global healthcare company with subsidiaries engaged in immuno-oncology, regenerative biologics, and medical device distribution.
This information is based on a press release statement from the company.
In other recent news, OSR Holdings, Inc. has made significant strides in its acquisition plans, announcing a strategic move to acquire South Korean medical device company Woori IO Co., Ltd. through its Korean affiliate. Under this proposed acquisition, Woori IO will become a wholly owned subsidiary, with shareholders having the opportunity to convert their shares into OSR Holdings common stock if certain conditions are met. Additionally, OSR Holdings has revealed plans for a $50 million security token offering in 2025, aimed at representing equity exposure and accepting various cryptocurrencies as subscription currencies.
In personnel changes, OSR Holdings appointed Dr. Andreas Niethammer as Chief Medical Officer of its subsidiary Vaximm AG, bringing his extensive experience in cancer immunotherapy and clinical development to the team. Meanwhile, the company announced the resignation of independent director Sang Hyun Kim from its board, clarifying that his departure was not due to any disagreements with the company. These developments reflect OSR Holdings’ ongoing strategic initiatives and organizational adjustments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.